Ultragenyx Pharmaceutical reported $-110M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Immunic USD -23.33M 2.67M Dec/2025
Insmed USD -81.83M 19.48M Sep/2026
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Kyowa Hakko Kirin JPY 26.41B 4.15B Sep/2026
MacroGenics USD -13.85M 19.59M Jun/2026
Moderna USD 130M 945M Sep/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
PTC Therapeutics USD 148.98M 103.09M Jun/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026